SCHEMBL15701667

SCHEMBL15701667

CCn1cc(I)c2cc(C(C)C)ccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORA P35398 1/20 0.38
RORC P51449 1/20 0.38
RORB Q92753 1/20 0.38
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
CYP19A1 P11511 5/20 0.33
SRC P12931 1/20 0.33
HTR6 P50406 1/20 0.33
CYP2C19 P33261 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
RAB9A P51151 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MAPT P10636 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
EDNRA P25101 1/20 0.32
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27112644 0.82 LMNA (0.39) RORARORCRORBCNR1CNR2
SCHEMBL15701664 0.81 RORA (0.41) RORARORCRORBCNR1CNR2
SCHEMBL15701668 0.81 RORA (0.38) RORARORCRORBCNR1CNR2
SCHEMBL15704208 0.78 KRAS (0.44) RORARORCRORBCNR2HTR6
SCHEMBL19626268 0.77 LMNA (0.50) CNR2CYP19A1HTR6CYP2C19RAB9A
SCHEMBL13084772 0.72 RORC (0.54) RORARORCRORBSRCKDM4E
SCHEMBL19089523 0.72 NR4A2 (0.50) CNR1CNR2CYP19A1ALDH1A1RAB9A
SCHEMBL12872413 0.69 NPC1 (0.49) SRCKDM4EALDH1A1HPGDRAB9A
SCHEMBL20594141 0.69 NR4A2 (0.51) CNR2HTR6KDM4EALDH1A1HPGD
SCHEMBL15701642 0.68 CYP19A1 (0.52) RORCCYP19A1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346795-B2 Substituted sulfonamides useful as antiapoptotic Bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-24 US disclosed
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 RORA 4143/4885RORC 4212/4885RORB 4070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.